Enanta Pharmaceuticals, Inc.
General ticker "ENTA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $278.5M (TTM average)
Enanta Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 10.2%.
Estimated limits based on current volatility of 2.9%: low 11.01$, high 11.68$
Factors to consider:
- Total employees count: 120 (-8.4%) as of 2025
- Top business risk factors: Need additional capital, Market competition, Regulatory and compliance, Clinical trial failure, Intellectual property risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [7.49$, 17.91$]
- 2026-09-30 to 2027-09-30 estimated range: [6.06$, 14.90$]
Financial Metrics affecting the ENTA estimates:
- Negative: with PPE of -2.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Positive: Interest expense per share per price, % of 3.94 <= 4.56
- Negative: Industry earnings per price (median), % of -20.06 <= 0
- Positive: 12.78 < Shareholder equity ratio, % of 23.05 <= 25.20
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ENTA quotes
Long-term ENTA plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | $79.20MM | $67.64MM | $65.32MM |
| Operating Expenses | $216.41MM | $189.33MM | $150.67MM |
| Operating Income | $-137.21MM | $-121.69MM | $-85.35MM |
| Non-Operating Income | $6.21MM | $3.90MM | $1.80MM |
| Interest Expense | $5.15MM | $10.94MM | $7.68MM |
| R&D Expense | $163.52MM | $131.48MM | $106.74MM |
| Income(Loss) | $-131.00MM | $-117.79MM | $-83.55MM |
| Taxes | $2.82MM | $-1.74MM | $-1.66MM |
| Net Income(Loss)* | $-133.82MM | $-116.05MM | $-81.89MM |
| Stockholders Equity | $216.74MM | $128.81MM | $64.72MM |
| Assets | $462.27MM | $376.65MM | $280.73MM |
| Operating Cash Flow | $-103.15MM | $-78.76MM | $-19.27MM |
| Capital expenditure | $9.06MM | $17.95MM | $12.90MM |
| Investing Cash Flow | $-53.58MM | $58.23MM | $40.35MM |
| Financing Cash Flow | $198.13MM | $-27.63MM | $-26.62MM |
| Earnings Per Share** | $-6.38 | $-5.48 | $-3.84 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.